Does Insight Molecular Diagnostics Inc. have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores Insight Molecular Diagnostics Inc. (IMDX) 28.4 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 29, returns on capital 0, balance-sheet safety 55, capital discipline 44.

How has IMDX's Moat Score changed over time?

The record logs 2 readings since Jul 17, 2026; the latest reads 28.4 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

Insight Molecular Diagnostics Inc.

IMDX · Healthcare · $136.0M mkt cap · FY2025 filings · No moat ·

Doesn't clear the bar

No moat

The four filters

Pricing power29

Median gross margin 33.4% over 6y, variable.

Returns on capital0

Median ROIC -131.5%, above the 9% hurdle in 0% of years.

Balance-sheet safety55

Net cash position — no leverage risk.

Capital discipline44

Owner earnings trend unclear, share count n/a.

Margin of safety

Above valueOn sale

No price data

Owner earnings (normalized): —
Est. intrinsic value / share: —
Recent price: $4.74
Discount to value: No price data

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

Fundamentals

There's no normalized fundamentals series for IMDX yet — it appears once ingest has processed its filings.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale28.4 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — IMDX has read No moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#359 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#357CFOO China Foods Holdings Ltd.28.7 out of 100, No moatNo moat
#358HURC HURCO COMPANIES, INC.28.4 out of 100, No moatNo moat
#360CRMD CORMEDIX INC.27.9 out of 100, No moatNo moat
#361RXST RxSIGHT, INC.27.5 out of 100, No moatNo moat

Compare IMDX with its nearest peers →All Healthcare companies on the Index →

Common questions about IMDX

Does Insight Molecular Diagnostics Inc. have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores Insight Molecular Diagnostics Inc. (IMDX) 28.4 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 29, returns on capital 0, balance-sheet safety 55, capital discipline 44.
How has IMDX's Moat Score changed over time?: The record logs 2 readings since Jul 17, 2026; the latest reads 28.4 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows IMDX’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/IMDX"
  width="340" height="150" style="border:0"
  title="IMDX Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell IMDX. See the disclaimer.